Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
PFE 
Pfizer Inc (PFE)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
07/15/2025: PFE (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
25 Analysts rated it
Well-followed company, solid analyst reports, reliable data for confident investing.
1 Year Target Price $29.24
1 Year Target Price $29.24
| 7 | Strong Buy |
| 2 | Buy |
| 15 | Hold |
| 0 | Sell |
| 1 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -10.47% | Avg. Invested days 31 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 07/15/2025 |
Key Highlights
Company Size Large-Cap Stock | Market Capitalization 144.12B USD | Price to earnings Ratio 18.37 | 1Y Target Price 29.24 |
Price to earnings Ratio 18.37 | 1Y Target Price 29.24 | ||
Volume (30-day avg) 25 | Beta 0.49 | 52 Weeks Range 20.53 - 29.98 | Updated Date 07/15/2025 |
52 Weeks Range 20.53 - 29.98 | Updated Date 07/15/2025 | ||
Dividends yield (FY) 7.10% | Basic EPS (TTM) 1.38 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin 12.62% | Operating Margin (TTM) 35.17% |
Management Effectiveness
Return on Assets (TTM) 4.79% | Return on Equity (TTM) 8.62% |
Valuation
Trailing PE 18.37 | Forward PE 8.68 | Enterprise Value 188099017630 | Price to Sales(TTM) 2.31 |
Enterprise Value 188099017630 | Price to Sales(TTM) 2.31 | ||
Enterprise Value to Revenue 3.01 | Enterprise Value to EBITDA 10.91 | Shares Outstanding 5685369856 | Shares Floating 5675927880 |
Shares Outstanding 5685369856 | Shares Floating 5675927880 | ||
Percent Insiders 0.06 | Percent Institutions 67.55 |
Upturn AI SWOT
Pfizer Inc
Company Overview
History and Background
Pfizer Inc. was founded in 1849 by Charles Pfizer and Charles Erhart in New York City. Initially, it produced fine chemicals, but it quickly expanded into pharmaceuticals. Key milestones include the development of penicillin during World War II and the introduction of blockbuster drugs like Viagra and Lipitor.
Core Business Areas
- Biopharmaceuticals: Focuses on innovative medicines and vaccines, including therapies for oncology, inflammation & immunology, rare diseases, and vaccines.
Leadership and Structure
Albert Bourla serves as the Chairman and CEO. The organizational structure is divided into various business units based on therapeutic areas and functions such as research, development, and commercial operations.
Top Products and Market Share
Key Offerings
- Comirnaty (COVID-19 Vaccine): An mRNA vaccine developed in partnership with BioNTech. Revenue in 2023 was $11.2 billion. Competitors include Moderna and Novavax.
- Paxlovid (COVID-19 Treatment): An oral antiviral for the treatment of COVID-19. Revenue in 2023 was $1.3 billion. Competitors include Gilead Sciences.
- Prevnar Family: A pneumococcal vaccine. It prevents pneumococcal disease. Competitors include Merck (Pneumovax 23).
Market Dynamics
Industry Overview
The pharmaceutical industry is characterized by high R&D costs, stringent regulatory requirements, and increasing competition from generic drugs. Trends include personalized medicine, gene therapy, and biosimilars.
Positioning
Pfizer is a leading global pharmaceutical company with a strong portfolio of innovative medicines and vaccines. Its competitive advantages include its extensive R&D capabilities, global reach, and strong brand recognition.
Total Addressable Market (TAM)
The global pharmaceutical market is estimated to be over $1 trillion. Pfizer is well-positioned to capture a significant share of this market due to its diverse portfolio and global presence.
Upturn SWOT Analysis
Strengths
- Strong R&D capabilities
- Global presence and distribution network
- Diverse portfolio of products
- Strong brand recognition
- Significant financial resources
Weaknesses
- Dependence on key products (patent cliffs)
- Exposure to generic competition
- High R&D costs
- Litigation risks
- Integration risks from acquisitions
Opportunities
- Expanding into emerging markets
- Developing new therapies for unmet medical needs
- Acquiring promising biotech companies
- Leveraging digital technologies
- Partnerships to expand product portfolios
Threats
- Increasing competition from generic and biosimilar drugs
- Stringent regulatory requirements
- Price pressures from governments and payers
- Product liability lawsuits
- Economic downturns affecting healthcare spending
Competitors and Market Share
Key Competitors
- JNJ
- MRK
- ABBV
- NVS
- BMY
Competitive Landscape
Pfizer faces intense competition from other large pharmaceutical companies. Its competitive advantages include its strong R&D capabilities and global reach, but it also faces challenges from generic competition and price pressures.
Major Acquisitions
Arena Pharmaceuticals
- Year: 2022
- Acquisition Price (USD millions): 6700
- Strategic Rationale: Expanded Pfizer's capabilities in gastroenterology and inflammation & immunology.
Growth Trajectory and Initiatives
Historical Growth: Pfizer's growth has been driven by successful product launches, acquisitions, and expansion into new markets. However, patent expirations and competition have impacted growth at times.
Future Projections: Analysts project moderate revenue growth in the coming years, driven by new product launches and expansion in emerging markets. Earnings growth is expected to be higher due to cost-cutting measures and operational efficiencies.
Recent Initiatives: Pfizer is focusing on developing innovative therapies for oncology, inflammation & immunology, and rare diseases. It is also investing in digital technologies and personalized medicine.
Summary
Pfizer is a global pharmaceutical giant with a strong portfolio and extensive reach. While facing challenges from patent expirations and competition, its robust R&D and strategic acquisitions support future growth. Monitoring new product pipeline and maintaining financial stability will be critical. Demand swings in COVID products, and other risks can significantly affect their outlook and must be watched for by investors
Peer Comparison
Sources and Disclaimers
Data Sources:
- Pfizer's Investor Relations Website
- SEC Filings
- Analyst Reports
- Company Press Releases
Disclaimers:
The data provided is for informational purposes only and should not be considered investment advice. Market share data is approximate and based on available estimates. Actual results may vary.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Pfizer Inc
Exchange NYSE | Headquaters New York, NY, United States | ||
IPO Launch date 2012-08-13 | Chairman of the Board & CEO Dr. Albert Bourla D.V.M., Ph.D. | ||
Sector Healthcare | Industry Drug Manufacturers - General | Full time employees 81000 | Website https://www.pfizer.com |
Full time employees 81000 | Website https://www.pfizer.com | ||
Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular and migraine under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands. It also provides medicines and vaccines in various therapeutic areas, such as biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Litfulo, Velsipity, and Cibinqo brands; amyloidosis, hemophilia, endocrine diseases, and sickle cell disease under the Vyndaqel family, Oxbryta, BeneFIX, Somavert, Ngenla, and Genotropin brands; sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Zavicefta, Zithromax, Octagam, and Panzyga brands; and biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Padcev, Adcetris, Inlyta, Lorbrena, Bosulif, Tukysa, Braftovi, Mektovi, Orgovyx, Elrexfio, Tivdak, and Talzenna brands. In addition, the company involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, individual provider offices, retail pharmacies, and integrated delivery systems. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.